... cells taken from a patient who has remained tumor-free for more than a decade, they found naturally-arising T cells ... 1-specific T cells with relapse-free survival suggests that amplifying these T cells ...
... placebo. However, there was clear evidence of clinical activity with improvements in progression-free survival and response rate when bevacizumab was added to erlotinib compared to erlotinib alone.
...
... in this large-scale study without routine angiographic follow-up and sets a new standard for event-free survival after [implantation of a drug-eluting stent]," said principal ...
... Journal of the National Cancer Institute. This study was undertaken to examine whether progression-free survival (PFS) or OS is the most appropriate endpoint in clinical trials of metastatic cancer, ...
... 6.4-month expected progression-free survival in these patients.
Study patients lived ... 14.3 months.
“We’re more than doubling survival time in this group, and we have some patients who are four, five ...
... statistically significant benefit to infants in terms of HIV-free survival at 24 months, compared to those infants who ... stopped breast-feeding at four months survived to 24 months of age versus 75 ...
... stages.
At the congress, Dr. Cognetti reports results from a median follow-up of 62 months, showing a disease-free survival rate of 74% in the docetaxel arm, compared to 68% ...
... no statistically significant impact on transplant-related mortality, relapse, leukemia-free survival or overall survival.
"These findings will be important in changing practice for the treatment of ...
... seriousness of the tumor, the two-year disease free survival, or cure rate through SBRT ... cure at least half of the patients.
"Such high survival rates are equivalent to other techniques, like invasive ...
... .
Patients experienced varying levels of improvement. Among those with breast cancer, the period of progression-free survival increased for 44 percent of patients; for colorectal, 36 percent of ...
... who drank wine had a 76 percent five-year survival compared with 68 percent for non-wine drinkers. Further research found five-year, disease-free survival was 70 percent among those who drank wine ...
... likely to have a relapse, and at three-years after completing therapy, the rate of relapse-free survival was 68 percent in the capecitabine group versus 85 percent in the standard-chemotherapy group.
... donor) is associated with significant overall and relapse-free survival benefit among adult patients ... AML, and a lack of significant RFS or overall survival benefit for good-risk AML," the authors ...
... a compatible donor) is associated with significant overall and relapse-free survival benefit among adult patients with intermediate- and poor-risk but not good-risk acute myeloid leukemia ...
... (range 2.4 to 7.4) for the 30 surviving patients. Although not a direct comparison, the results ... experienced remarkable long-term, progression-free survival after completing the vaccine therapy, even ...
